Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
244
resultados
Última actualización
17/04/2026 [07:22:00]
Resultados 25 a 50 de 244
Resumen de: WO2026071006A1
The present invention is such that a test substance derived from an amyloid-β precursor protein in a blood sample, a substance that binds to the test substance, and a buffer solution are brought into contact for 6 minutes or less. The buffer solution contains a buffering agent where the concentration at the time of contact is 25 mM or more, and is such that the pH is 3.5 to 9.0. A signal derived from the binding between the test substance and the substance binding to the test substance is measured.
Resumen de: US20260092931A1
Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.
Resumen de: WO2026071242A1
The present invention addresses the problem of providing: a nerve cell analysis method with which the localized amount of TDP-43 in nerve cells can be analyzed without labeling TDP-43 with a fluorescent tag or the like and without carrying out gene transfer; a kit for carrying out the nerve cell analysis method; and a screening method for a prophylactic and/or therapeutic agent for a neurodegenerative disease. The present invention provides a nerve cell analysis method involving: a staining step for immunofluorescent staining of nerve cells using an anti-TDP-43 antibody and an antibody that recognizes a stress granule marker; a cell region identification step for identifying the cytoplasm and nuclei of the nerve cells; and an analysis step for analyzing a TDP-43-derived fluorescence signal and a stress granule marker-derived fluorescence signal in the cytoplasm, and analyzing the localized amount of TDP-43 in the nerve cells on the basis of the presence or absence of colocalization of a granular TDP-43 signal and a granular stress granule marker signal in the cytoplasm.
Resumen de: US20260092110A1
0000 The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.
Resumen de: US20260092926A1
0000 There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.
Resumen de: EP4718076A2
The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/ or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.
Resumen de: WO2025018933A1
The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.
Resumen de: CA2106077A1
2106077 9216902 PCTABS00016 A data processing pension plan monitor (40) is directed specifically to the management and controlled access of pensionbacked credit (AC). This system permits pension plan participants to establish a line of credit (LOC), based on their vested interest in a sponsored pension plan (10). This LOC is thereafter systematically applied to a plurality of account (80, 90), each permitted selected credit card (90) and/or check writing privileges. The charges associated with the credit accessed are paid back to the pensioner, thereby retaining certain tax deferred privileges while permitting access to the accumulated funds.
Resumen de: US2018099049A1
Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C.
Resumen de: US20260083826A1
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.
Resumen de: US20260086093A1
0000 The present invention relates to methods for the determination of the residence time between at least one Target and at least one Ligand, optionally in their native biological context, using limited proteolysis e.g., combined with selected reaction monitoring, parallel reaction monitoring, data-independent acquisition (DIA), including Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra (SWATH) methods and the like.
Resumen de: US20260086086A1
0000 Embodiments may include a rapid test device that provide rapid detection of substances, including those involved in pathogen infection, for example, using Microscale Affinity Chromatography (MAC), indirect ELISA, and optical molecular sensing technology. For example, in an embodiment, an apparatus may comprise a loading bay disposed on the apparatus to receive a cartridge, a door disposed on the apparatus to cover the loading bay, a plurality of prongs disposed on an interior of the door to provide actuation force to dispense blister reservoirs disposed on the cartridge when the door is closed, and a device disposed relative to the cartridge to move at least a portion of contents of the cartridge among chambers of the cartridge.
Resumen de: US20260085112A1
The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.
Resumen de: WO2026064441A1
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42/40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS/MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42/40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.
Resumen de: WO2026063647A1
The present invention relates to an antibody specifically binding to TDP-43 and use thereof. When the antibody of the present invention is used, the level of TDP-43, particularly TDP-43 aggregates, can be effectively detected. Therefore, the present invention can be a powerful tool for distinguishing TDP-43 proteinopathy from other clinically similar neurodegenerative diseases and diagnosing TDP-43 proteinopathy, serving as a biomarker for TDP-43 proteinopathy, including FTD, ALS, LATE, and the like.
Resumen de: DE102024127976A1
Eine mikrofluidische Vorrichtung (12) zum Probenauftrag einer Körperflüssigkeit auf ein konditioniertes Sensorelement für eine Detektion von molekularen Biomarkern in der Körperflüssigkeit und/oder zum Konditionieren des Sensorelements (14) mittels eines Konditionierungsfluids umfasst zumindest eine Interaktionskammer (40), die abschnittsweise durch ein Sensorelement (14) geschlossen ist. Eine Pneumatikeinheit (70) ist mit der zumindest einen ersten Aufnahme (46) verbunden und dazu eingerichtet, diese mit Überdruck zu beaufschlagen und die Körperflüssigkeit oder das Konditionierungsfluid durch die zumindest eine Interaktionskammer (40) entlang der behandelten Oberfläche (16) einmalig und unidirektional und anschließend in den zumindest einen Entsorgungsbehälter (52) zu pumpen, so dass bei Körperflüssigkeit Biomarker an der Oberfläche (16) haften oder bei Konditionierungsfluid die Oberfläche konditioniert ist. Ferner werden eine Biomarkerdetektionsvorrichtung (18) und eine Verfahren zum Probenauftrag einer Körperflüssigkeit auf ein konditioniertes Sensorelement (14) für eine Biomarkerdetektion und/oder zum Konditionieren eines Sensorelements (14) für eine Biomarkerdetektion vorgeschlagen.
Resumen de: WO2026064744A1
The subject invention provides materials and methods for treating diseases affecting the central nervous system (CNS) and/or other viral reservoir organs utilizing nanoscopic diamond particles, i.e., nanodiamonds (ND), loaded with drug molecules and microglial targeting moiety.
Resumen de: US20260086100A1
0000 Provided are methods of determining risk for chronic stress and stroke. More specifically, provided is an early prognostic index that can be used to predict chronic stress and stroke risk. There is provided a method of evaluating the risk of developing chronic stress and stroke, the method including obtaining a biological sample from an individual; measuring the levels of a set of biomarkers in the biological sample obtained from the individual; measuring the levels of a set of clinical markers of the individual; using a computer to programmatically generate an index based on the levels of biomarker in the biological sample obtained from the individual in combination with levels of the individual's clinical marker; and using the index to identify a likelihood that the individual will experience chronic stress and stroke.
Resumen de: US20260086063A1
0000 Circulatory failure generates hypoxia and leads to accumulation of reductive species in tissue and circulatory failure monitoring tools are needed but rare. Cardiopulmonary bypass (CPB) is known to promote brief circulatory failure during its initiation. In the present study, the Inventors demonstrate a correlation between whole blood redox potential and circulatory failure during (CPB). They made a prospective study with 17 patients eligible for cardiac surgery with cardiopulmonary bypass. They demonstrated a frank reduction of the whole blood redox potential during circulatory failure during the initiation of CPB. They also demonstrated that they were able to classify patients in 3 groups, one of them presenting an unfavorable post-operative outcome. Accordingly, the present invention relates to a method of diagnosing acute circulatory failure in a patient comprising determining the level of redox potential in a sample obtained from said patient, wherein the level of redox potential indicates whether the patient suffers or not from an acute circulatory failure.
Resumen de: WO2026064655A1
Provided are nucleic acids encoding voltage indicator polypeptides. In some instances, the voltage indicator polypeptide comprises a voltage-sensing domain (VSD) comprising four transmembrane segments, and a circularly permuted fluorescent protein inserted into an extracellular loop between the third transmembrane segment (S3) and the fourth transmembrane segment (S4) of the VSD. The voltage indicator polypeptide may comprise one or more amino acid substitutions and/or deletions, non-limiting examples of which include one or more substitutions at I412, F413 and/or Q414, wherein numbering of positions is according to SEQ ID NO: 1. Cells comprising the nucleic acids are also provided. In some embodiments, the cells are neurons that express the voltage indicator polypeptide on the plasma membrane of the neuron in a pan-membrane or targeted manner. Methods of recording the electrical activity of neurons are also provided, as are methods of assessing an effect of an agent on the electrical activity of neurons.
Resumen de: WO2026062142A1
The invention relates to a circuit carrier (2), PCB, for a clip (1) for mounting on an absorbent article (4). The circuit carrier (2) comprises an impedance and electrochemical sensing module (21) configured to obtain a first measurement signal, a gas sensing module (22) configured to obtain a second measurement signal, a motion and position sensing module (23) configured to obtain a third measurement signal, a temperature sensing module (24) configured to obtain a fourth measurement signal, and a main controller (29) configured to control an operation of the sensing modules (21, 22, 23, 24) for obtaining the measurement signals, to sample and process the obtained measurement signals from the sensing modules (21, 22, 23, 24) and determine an output based on the sampled measurement signals, wherein the main controller (29) comprises a communication unit configured to exchange the measurement signals and/or the determined output with an external device and/or a server using an radio-frequency, RF, module, a gateway and a wireless personal area network transmission, WPAN, protocol, and/or using serial data transmission. The invention further relates to a clip (1) comprising the circuit carrier (2) according to the invention.
Resumen de: AU2024327213A1
A method of determining a health status of an individual, the method comprising the steps of assaying a biological sample from the individual for the positive expression of SAA1 and/or SAA2, and wherein the positive expression of the SAA1 and/or SAA2 above or below a threshold expression level in a control sample correlates with the health status of the individual.
Resumen de: CN121152975A
The present invention relates to the use of biomarkers for measuring the efficacy or effectiveness of a treatment for neurodegenerative diseases, in particular Alzheimer's disease.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Nº publicación: JP2026509766A 25/03/2026
Solicitante:
キーバイオサイエンス・ソチエタ・アノニマ
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
BOPI
Sede Electrónica
